Phase II Clinical Data going for third party reviewPhase II Clinical Data going for third party review
"Arch Biopartners Inc. has provided an update that the analysis of the results of the phase II trial of its lead drug LSALT peptide (metablok) is continuing and will be disclosed to the public following third party, scientific peer review."
ARCH.V - 56% held by insiders
Canadian Innovation Funded Phase II humna trial on Organ inflammation